NewAmsterdam Pharma Warrant
NAMSW
18 hedge funds and large institutions have $4.73M invested in NewAmsterdam Pharma Warrant in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1.83% more ownership
Funds ownership: 0% → 1.83% (+1.8%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
5% less capital invested
Capital invested by funds: $5M → $4.73M (-$272K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$26.8K |
| 2 |
Walleye Capital
New York
|
+$13.5K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$10.7K |
| 4 |
Walleye Trading
New York
|
+$7.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETH
Exos TFP Holdings
New York
|
-$154K |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$40.5K |
| 3 |
MTCM
Mint Tower Capital Management
Amsterdam,
Netherlands
|
-$12K |
| 4 |
CS
Clear Street
New York
|
-$8.94K |
NAMSW Hedge Fund Activity: Q2 2023 in Review
18 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q2 2023, worth a combined $4.73M — down 5.4% from $5M a quarter earlier.
Fund positioning in NAMSW was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $26.8K. The largest seller was Exos TFP Holdings, cutting an estimated $154K.
- 18 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $4.73M of NewAmsterdam Pharma Warrant stock for Q2 2023, down 5.4% quarter-over-quarter.
- 2 funds opened new NewAmsterdam Pharma Warrant positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest NewAmsterdam Pharma Warrant buyer in Q2 2023 was Wolverine Asset Management, an estimated $26.8K added.
- The largest NewAmsterdam Pharma Warrant seller in Q2 2023 was Exos TFP Holdings, an estimated $154K sold.
Based on aggregated 13F filings for Q2 2023.